Genpact's Q2 Beat Looks Solid-But 25% ATS Growth Is Now the Only Number That Matters

Genpact's Q2 beat was clean, but the real question is the mix shift

Genpact delivered a solid second quarter: revenue was $1.343 billion, up 7.1%, and adjusted EPS reached $1.00, up 13.6%, above consensus of $0.96 per share and $1.33 billion in sales. For a services company, that is the kind of report that looks competent and broadly in line with expectations.

The more important question is not whether the quarter was good. It is whether the faster-growing part of the business is becoming important enough to matter to valuation. That piece is Advanced Technology Solutions (ATS), where Genpact is selling more AI, data, digital, and advisory outcomes and less purely volume-driven service work. Management now expects ATS revenue to grow at least 25% for the full year, up from its prior expectation of at least 20%, after Q2 ATS revenue rose 24.1% to $363 million, or 27% of total net revenues.

This quarter matters because the strategy is no longer only a narrative. It is starting to show up in the operating mix.

Non-FTE above 50% signals a better revenue mix

Genpact's mix is tilting away from pure labor scaling. Non-FTE revenue surpassed 50% for the first time, while Advanced Technology Solutions net revenues were $363 million, or 27% of total revenues. That combination matters because non-FTE revenue typically reflects more fixed-fee, consumption-based, and outcome-based work rather than simple headcount-based delivery.

If investors continue to value Genpact mostly as an outsourcing firm, that shift may stay underappreciated. If even part of the business starts being valued as a higher-value technology and outcomes provider, the multiple could move over time.

Thirteen straight quarters of gross margin expansion add credibility

The clearest check on the story is profitability. Gross margin has now expanded for 13 consecutive quarters, reaching 36.5%. That does not prove the mix shift is fully de-risked, but it does suggest the company is preserving pricing discipline while the business mix evolves.

The long-term logic is straightforward: if more revenue comes from ATS and non-FTE work, Genpact should become less dependent on growing strictly through labor hours. For now, the quarter supports that direction rather than contradicting it.

The 25% ATS target is now the main test

The market already knows Genpact has AI demand. The harder question is whether that demand is large enough to change the business materially.

Management has set the bar at at least 25% ATS growth in 2026, and the company said it is on track to book more than $1 billion in agentic contract value in 2026. That makes ATS the central watchpoint for the next few quarters.

The key signals are simple: - whether ATS keeps gaining share from its 27% base - whether non-FTE stays above half of revenue - whether margin discipline continues

What Q3 needs to confirm

The last report showed Genpact could execute. The next report needs to show the mix shift is still doing the heavy lifting.

The next-quarter scorecard

Management has already raised its full-year view to at least 12% adjusted diluted EPS growth for 2026. If Q3 revenue support remains around or above the market's $1.33 billion in sales expectations, that would suggest the momentum is carrying through rather than fading after one strong quarter.

What would weaken the case

The practical test is not buzzword density. It is whether revenue support, earnings guidance, and margin trends remain constructive in the next update. If those signals hold, the rerating case becomes easier to defend. If they slip, the market is more likely to treat ATS as a helpful add-on rather than the main engine of the story.